The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia

‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

(2017) Lieven Annemans et al.   EUROPEAN HEART JOURNAL

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

(2017) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association

(2017) Jerome D. Cohen et al.   Journal of Clinical Lipidology

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

(2017) Carl E. Orringer et al.   Journal of Clinical Lipidology

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2017) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cognitive Function in a Randomized Trial of Evolocumab

(2017) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia

(2017) Michael J. Koren et al.   JAMA Cardiology

Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers

(2017) Alejandro Arrieta et al.   JAMA Cardiology

Cost-effectiveness of PCSK9 Inhibitors

(2017) Robert O. Bonow et al.   JAMA Cardiology

Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease

(2017) Gregg C. Fonarow et al.   JAMA Cardiology

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin

(2017) Robert P. Giugliano et al.   JAMA Cardiology

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

(2016) Eli M. Roth et al.   ATHEROSCLEROSIS

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial

(2016) Michel Farnier et al.   ATHEROSCLEROSIS

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

(2016) Henry N. Ginsberg et al.   CARDIOVASCULAR DRUGS AND THERAPY

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

(2016) Shravanthi R. Gandra et al.   CLINICAL CARDIOLOGY

Determining When to Add Nonstatin Therapy

(2016) Jennifer G. Robinson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2016) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels

(2016) Jeffrey A. Tice et al.   JAMA Internal Medicine

Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk

(2016) Michel Farnier   Current Cardiology Reports

Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting

(2016) Ricardo Dent et al.   SpringerPlus

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

(2015) Dean J. Kereiakes et al.   AMERICAN HEART JOURNAL

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition

(2015) Nathalie Bergeron et al.   CIRCULATION

Heart Disease and Stroke Statistics—2016 Update

(2015) Dariush Mozaffarian et al.   CIRCULATION

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

(2015) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

(2015) Harold Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

(2015) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk

(2014) Atsushi Hirayama et al.   CIRCULATION JOURNAL

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

(2013) Evan A. Stein et al.   CIRCULATION

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

(2012) Frederick Raal et al.   CIRCULATION

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE